Travere Therapeutics Turns a Rare Disease Approval into Two Quarters of Accelerating Sales
The Food and Drug Administration granted Travere Therapeutics full approval for FILSPARI in focal segmental glomerulosclerosis on April 13, 2026, the drug’s second full approval after a 2023 clearance for IgA nephropathy. Travere’s stock rose 43 percent the next day, closing at $43.81. The DUPLEX Data Behind a Second Approval FSGS damages the kidney’s filtering […]
AI brief
Pulse reads the full article- What happened
- Why it matters
- What to watch
Sign in to get the AI brief. Pulse explains what happened, why it matters, what to watch and who's exposed. Free for members.
Sign in to read the brief